Amneal Pharmaceuticals (AMRX) Tax Provisions (2017 - 2026)

Amneal Pharmaceuticals' Tax Provisions history runs 10 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Tax Provisions fell 83.09% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $584000.0, a 97.72% decrease from a year earlier, with the FY2025 full-year figure at $11.3 million, down 40.22% from the prior year.
• Tax Provisions declined to $2.2 million in Q1 2026 per AMRX's latest filing, from $5.7 million in the prior quarter.
• Across five years, Tax Provisions topped out at $16.1 million in Q2 2025 and bottomed at -$23.4 million in Q3 2025.
• The 5-year median for Tax Provisions is $4.1 million (2022), against an average of $3.0 million.
• Across the five-year window, Tax Provisions slumped 965.25% in 2022 and jumped 779.43% in 2024, its largest moves.
• Year by year, Tax Provisions stood at -$1.8 million in 2022, then jumped by 637.7% to $9.9 million in 2023, then plunged by 45.13% to $5.4 million in 2024, then increased by 4.41% to $5.7 million in 2025, then plunged by 61.57% to $2.2 million in 2026.
• Per Business Quant, the three latest AMRX Tax Provisions figures stand at $2.2 million (Q1 2026), $5.7 million (Q4 2025), and -$23.4 million (Q3 2025).